Mouse models of transthyretin amyloidosis

Recent Advances in Transthyretin Evolution, Structure and Biological Functions

Volumn , Issue , 2009, Pages 261-280

  Ito, Sadahiro ^a   Maeda, Shuichiro ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Amyloid; Animal model; Genetically altered mouse; Knockout mouse; Serum amyloid P component; Transgenic mouse; Transthyretin amyloidosis

Indexed keywords

EID: 84896503397     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-00646-3_16     Document Type: Chapter

References (52)

1. Benson MD, Cohen AS (1977) Generalized amyloid in a family of Swedish origin: A study of 426 family members in seven generations of a new kinship with neuropathy nephropathy and central nervous system involvement. Ann Intern Med 86:419-424
2. Benson MD, Kincaid JC (2007) The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 36:411-423
3. Benson MD, Kluve-Beckerman B, Zeldenrust SR et al. (2006) Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve 33:609-618
4. Bergethon PR, Sabin TD, Lewis D et al. (1996) Improvement in the polyneuropathy associated with familial amyloid polyneuropathy after liver transplantation. Neurology 47:944-951
5. Bickerstaff MC, Botto M, Hutchinson WL et al. (1999) Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 5:694-697
6. Botto M, Hawkins PN, Bickerstaff MCM et al. (1997) Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nature Med 3:855-859
7. Buxbaum J, Tagoe C, Gallo G et al. (2003) The pathogenesis of transthyretin tissue deposition: Lessons from transgenic mice. Amyloid 10(Suppl 1):2-6
8. Bygrave AE, Rose KL, Cortes-Hernandez J et al. (2004) Spontaneous autoimmunity in 129 and C57BL/6 mice-implications for autoimmunity described in gene-targeted mice. PLoS Biol 2:e243
9. Cardoso I, Saraiva MJ (2006) Doxycycline disrupts transthyretin amyloid: Evidence from studies in a FAP transgenic mice model. FASEB J 20:234-239
10. Episkopou V, Maeda S, Nishiguchi S et al. (1993) Disruption of the transthyretin gene results in mice with depressed levels of plasma retinol and thyroid hormone. Proc Natl Acad Sci USA 90:2375-2379
11. Garlanda C, Bottazzi B, Bastone A et al. (2005) Pentraxins at the crossroads between innate immunity inflammation matrix deposition and female fertility. Annu Rev Immunol 23:337-366
12. Holmgren G, Bergstrom S, Drugge U et al. (1992) Homozygosity for the transthyretin-Met30-gene in seven individuals with familial amyloidosis with polyneuropathy detected by restriction enzyme analysis of amplified genomic DNA sequences. Clin Genet 41:39-41
13. Holmgren G, Ericzon B-G, Groth C-G et al. (1993) Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 341:1113-1116
14. Holmgren G, Wikström L, Lundgren HE et al. (2004) Discordant penetrance of the trait for familial amyloidotic polyneuropathy in two pairs of monozygotic twins. J Intern Med 256:453-456
15. Horie K, Maeda S, Nishiguchi S et al. (1995) A replacement vector used to introduce subtle mutations into mouse genes. Gene 166:197-204
16. Iwanaga T, Wakasugi S, Inomoto T et al. (1989) Liver-specific and high-level expression of human serum amyloid P component gene in transgenic mice. Dev Genet 10:365-371
17. Kohno K, Palha JA, Miyakawa K et al. (1997) Analysis of amyloid deposition in a transgenic mouse model of homozygous familial amyloidotic polyneuropathy. Am J Pathol 150:1497-1508
18. Macedo B, Batista AR, Ferreira N et al. (2008) Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of Familial Amyloidotic Polyneuropathy. Biochim Biophys Acta 1782:517-522
19. Marrack P, Kappler J, Kotzin BL (2001) Autoimmune disease: Why and where it occurs. Nat Med 7:899-905
20. Murakami T, Yi S, Maeda S et al. (1992) Effect of serum amyloid P component level on transthyretin-derived amyloid deposition in a transgenic mouse model of familial amyloidotic polyneuropathy. Am J Pathol 141:451-456
21. Nagata Y, Tashiro F, Yi S et al. (1995) A 6-kb upstream region of the human transthyretin gene can direct developmental tissue-specific and quantitatively normal expression in transgenic mouse. J Biochem 117:169-175
22. Nakamura M, Ando Y, Nagahara S et al. (2004) Targeted conversion of the transthyretin gene in vitro and in vivo. Gene Ther 11:838-846
23. Noguchi H, Ohta M, Wakasugi S et al. (2002) Effect of the intestinal flora on amyloid deposition in a transgenic mouse model of familial amyloidotic polyneuropathy. Exp Anim 51:309-316
24. Olofsson BO, Backman C, Karp K et al. (2002) Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy Portuguese type. Transplantation 73:745-751
25. Palha JA, Episkopou V, Maeda S et al. (1994) Thyroid hormone metabolism in a transthyretin-null mouse strain. J Biol Chem 269:33135-33139
26. Pepys MB, Booth DR, Hutchinson WL et al. (1997) Amyloid P component. A critical review. Amyloid 4:274-295
27. Pepys MB, Herbert J, Hutchinson WL et al. (2002) Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417:254-259
28. Rozzo SJ, Allard JD, Choubey D et al. (2001) Evidence for an interferon-inducible gene Ifi202 in the susceptibility to systemic lupus. Immunity 15:435-443
29. Santos SD, Fernandes R, Saraiva MJ (2008) The heat shock response modulates transthyretin deposition in the peripheral and autonomic nervous systems. Neurobiol Aging. doi:10.1016/j. neurobiolaging.2008.04.001 (in press)
30. Sasaki H, Tone S, Nakazato M et al. (1986) Generation of transgenic mice producing a human transthyretin variant: A possible mouse model for familial amyloidotic polyneuropathy. Biochem Biophys Res Commun 139:794-799
31. Shimada K, Maeda S, Murakami T et al. (1989) Transgenic mouse model of familial amyloidotic polyneuropathy. Mol Biol Med 6:333-343
32. Sigurdsson E, Wisniewski T, Frangione B (2002) Infectivity of amyloid diseases. Trends Mol Med 8:411-413
33. Soma M, Tamaoki T, Kawano H et al. (2001) Mice lacking serum amyloid P component do not necessarily develop severe autoimmune disease. Biochem Biophys Res Commun 286:200-205
34. Sousa MM, Fernandes R, Palha JA et al. (2002) Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin Leu55Pro. Am J Pathol 161:1935-1948
35. Suhr O, Holmgren G, Steen L et al. (1995) Liver transplantation in familial amyloidotic polyneuropathy. Follow-up of the first 20 Swedish patients. Transplantation 60:933-938
36. Tagoe CE, French D, Gallo G et al. (2004) Amyloidogenesis is neither accelerated nor enhanced by injections of preformed fibrils in mice transgenic for wild-type human transthyretin: The question of infectivity. Amyloid 11:21-26
37. Takaoka Y, Ohta M, Miyakawa K et al. (2004) Cysteine 10 is a key residue in amyloidogenesis of human transthyretin Val30Met. Am J Pathol 164:337-345
38. Takaoka Y, Tashiro F, Yi S, Maeda S, Shimada K, Takahashi K et al. (1997) Comparison of amyloid deposition in two lines of transgenic mouse that model familial amyloidotic polyneuropathy type I. Transgenic Res 6 (4) 261-269
39. Tamaoki T, Tezuka H, Okada Y et al. (2005) Avoiding the effect of linked genes is crucial to elucidate the role of Apcs in autoimmunity. Nat Med 11:11-12
40. Tashiro F, Yi S, Wakasugi S et al. (1991) Role of serum amyloid P component for systemic amyloidosis in transgenic mice carrying human mutant transthyretin gene. Gerontology 37(suppl 1):56-62
41. Teng MH, Yin JY, Vidal R et al. (2001) Amyloid and nonfibrillar deposits in mice transgenic for wild-type human transthyretin: A possible model for senile systemic amyloidosis. Lab Invest 81:385-396
42. Tennent G, ALovat LB, Pepys MB (1995) Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci USA 92:4299-4303
43. Terazaki H, Ando Y, Fernandes R et al. (2006) Immunization in familial amyloidotic polyneuropathy: Counteracting deposition by immunization with a Y78F TTR mutant. Lab Invest 86:23-31
44. Togashi S, Lim S, Kawano H et al. (1997) Serum amyloid P component enhances induction of murine amyloidosis. Lab Invest 77:525-531
45. Ueda M, Ando Y, Hakamata Y et al. (2007) A transgenic rat with the human ATTR V30M: A novel tool for analyses of ATTR metabolisms. Biochem Biophys Res Commun 352:299-304
46. Usui I, Kawano H, Ito S et al. (2001) Homozygous serum amyloid P component-deficiency does not enhance regression of AA amyloid deposits. Amyloid 8:101-104
47. Wakasugi S, Inomoto T, Yi S et al. (1987) A transgenic mouse model of familial amyloidotic polyneuropathy. Proc Japan Acad 63(B):344-347
48. Wakel and EK, Liu K, Graham RR et al. (2001) Delineating the genetic basis of systemic lupus erythematosus. Immunity 15:397-408
49. Wei L, Kawano H, Fu X et al. (2004) Deposition of transthyretin amyloid is not accelerated by the same amyloid in vivo. Amyloid 11:113-120
50. Wei S, Episkopou V, Piantedosi R et al. (1995) Studies on the metabolism of retinol and retinolbinding protein in transthyretin-deficient mice produced by homologous recombination. J Biol Chem 270:866-870
51. Yamamura K, Tashiro F, Wakasugi S et al. (1990) Transgenic mouse model of autosomal dominant disease: Familial amyloidotic polyneuropathy. In: Beyreuther K Schttler G (ed) Molecular Mechanisms of Aging (pp 146-154) Springer-Verlag, Heidelberg.
52. Yi S, Takahashi K, Naito M et al. (1991) Systemic amyloidosis in transgenic mice carrying the human mutant transthyretin (Met 30) gene. Pathologic similarity to human familial amyloidotic polyneuropathy type I. Am J Pathol 138:403-412